Although the clinical development of vanucizumab for cancer treatment was discontinued following the finding of a similar PFS benefit with vanucizumab and bevacizumab in the overall McCAVE study population (i.e. the primary endpoint of the study was not met), the vessel stabilisation benefit provided by dual inhibition of Ang-2 and VEGF-A was further leveraged in ophthalmology in the treatment of neovascular age-related macular degeneration and visual impairment due to diabetic macular oedema, resulting in the development of the bispecific antibody faricimab (59). The gene discussed is VEGFA; the disease is age-related macular degeneration.